Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Rapid advancements in materials science and nanotechnology, intertwined with oncology,
have positioned photothermal therapy (PTT) as a promising noninvasive treatment strategy …

Indolent (lepidic) and aggressive (micropapillary, solid, and poorly differentiated acinar)
histologic subtypes often coexist within a tumor tissue of lung adenocarcinoma (LUAD), but …

Adenosine (Ado) mediates immune suppression in the tumor microenvironment and
exhausted CD8+ CAR-T cells express CD39 and CD73, which mediate proximal steps in …

Recurrence of advanced melanoma after therapy is a major risk factor for reduced survival,
and treatment options are limited. Antitumor immune memory plays a critical role in …

Stimulator of interferon genes (STING) pathway is the key innate immune pathway involving
in cancer immunity. Emerging new molecules and drug delivery systems have made …

The immune system plays critical roles in both autoimmunity and cancer, diseases at
opposite ends of the immune spectrum. Autoimmunity arises from loss of T cell tolerance …

Mutation burden, hypoxia, and immunoediting contribute to altered metabolic profiles in
tumor cells, resulting in a tumor microenvironment (TME) characterized by accumulation of …